SRI Earns FDA Orphan Drug Designation for Pancreatic Cancer
SRI Earns FDA Orphan Drug Designation for Pancreatic Cancer

SRI’s Targeted Antigen Loaded Liposomes (TALL) — a treatment that expands the benefits of immunotherapy such as check-point inhibitors — has been granted Orphan Drug Designation (ODD) for pancreatic ductal adenocarcinoma (PDAC) by the U.S. Federal…